Pan Chunyang, Zhao Yi, Xie Haojie, Zhou Yongyan, Duan Ranran, Li Yanfei, Jia Yanjie, Peng Tao
Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
Neuropsychiatr Dis Treat. 2021 Sep 7;17:2859-2866. doi: 10.2147/NDT.S322789. eCollection 2021.
To describe and compare the clinical features of patients with first-episode neuromyelitis optica spectrum disorder (NMOSD) in a normal complement C4 group and a low complement C4 group, and explore the mechanism by which low complement C4 affects the clinical features of patients with NMOSD.
We retrospectively analyzed clinical data of 169 aquaporin-4 (AQP4) antibody positive patients with NMOSD from the First Affiliated Hospital of Zhengzhou University from December 2013 to March 2021. Prior to treatment, the blood was drawn for detection, and the patients underwent a 3.0 Tesla MRI examination. A low complement C4 level was defined as a serum complement C4 level <0.14 g/L. Depending on whether the complement C4 level was reduced, it was divided into the normal complement C4 group and low complement C4 group. The basic demographics, clinical manifestations, laboratory examinations, and imaging findings of the two groups were compared.
Among the 169 AQP4 antibody positive patients, 54 were low-complement C4 patients and 115 were normal. There were no significant differences in the demographics, clinical manifestations, treatment options, or admission Expanded Disability Status Scale (EDSS) score between two groups (P > 0.05). The median of discharged EDSS was the same (4 vs 4), but the difference between the two was statistically significant (P = 0.019). Compared with the normal complement C4 group, the blood uric acid level (225 vs 179; P = 0.001) and the C3 level (1.06 vs 0.87, P = 0.000) of the low complement C4 group were significantly lower. The incidence of brainstem lesions in patients with low complement C4 was higher (53.7% vs 33%, P = 0.01).
The treatment effect of the first-episode AQP4 antibody positive NMOSD low complement C4 group was poor, the blood-brain barrier was more severely damaged, and the disease changes were likely to involve the brainstem.
描述和比较正常补体C4组与低补体C4组首次发作的视神经脊髓炎谱系障碍(NMOSD)患者的临床特征,探讨低补体C4影响NMOSD患者临床特征的机制。
回顾性分析2013年12月至2021年3月郑州大学第一附属医院169例水通道蛋白4(AQP4)抗体阳性的NMOSD患者的临床资料。治疗前采血检测,并对患者进行3.0特斯拉MRI检查。低补体C4水平定义为血清补体C4水平<0.14g/L。根据补体C4水平是否降低,分为正常补体C4组和低补体C4组。比较两组的基本人口统计学、临床表现、实验室检查和影像学表现。
169例AQP4抗体阳性患者中,低补体C4患者54例,正常患者115例。两组在人口统计学、临床表现、治疗方案或入院时扩展残疾状态量表(EDSS)评分方面无显著差异(P>0.05)。出院时EDSS中位数相同(4对4),但两组间差异有统计学意义(P=0.019)。与正常补体C4组相比,低补体C4组的血尿酸水平(225对179;P=0.001)和C3水平(1.06对0.87,P=0.000)显著降低。低补体C4患者脑干病变发生率较高(53.7%对33%,P=0.01)。
首次发作的AQP4抗体阳性NMOSD低补体C4组治疗效果差,血脑屏障受损更严重,病情变化可能累及脑干。